Investor Relations
Partnerships are integral to Harbour BioMed's strategy to build a fully integrated biopharmaceutical company.
Analyst(s) | Firm |
Sean Wu | Morgan Stanley |
David Li | BAML |
Tony Ren | CLSA |
Yang Huang | Credit Suisse |
Yuanyuan Sun, Jiaxi Xu | Industrial Securities |
Linda Shu, Edison Kong | Haitong International Securities |
Juying He, Qinghui Yuan | China Securities |
Xiaowei Lin, Mingrui Wang | Everbright Securities |
Xingqiu Lin | Guoyuan International |
Hao Liu, Yue Gao | Hua Chuang Securities |
Ningda Zhao, Ziyue Xu | Essence International |
This list of analysts was prepared based on material that was available at the time of writing. Therefore, please note that there may be other analysts who have not been included in this list, and that some of the information may not be the latest.
Please note that the analysts have conducted their own analyses of the Company's performance, businesses, products and technologies, and have developed their own forecasts. These processes do not in any way involve the Company or the management of the Company.